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Ocular allergy represents one of the most common conditions encountered by allergists and ophthalmologists.
Allergic conjunctivitis is often underdiagnosed and consequently undertreated. Basic and clinical research has
provided a better understanding of the cells, mediators, and immunologic events, which occur in ocular allergy.
New pharmacological agents have improved the efficacy and safety of ocular allergy treatment. An understanding
of the immunologic mechanisms, clinical features, differential diagnosis, and treatment of ocular allergy may be
useful to all specialists who deal with these patients. The purpose of this review is to systematically review literature
underlining all the forms classified as ocular allergy: seasonal allergic conjunctivitis, perennial allergic conjunctivitis,
vernal keratoconjunctivitis, atopic keratocongiuntivitis, contact allergy, and giant papillary conjunctivitis.
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Allergic diseases have dramatically increased in the last
decades [1-4]. Ocular allergy represents one of the most
common ocular conditions encountered in clinical prac-
tice. A single cause of this increase cannot be pinpointed
and experts are therefore considering the contribution
of numerous factors, including genetics, air pollution in
urban areas, pets, and early childhood exposure [5]. The
associated costs have increased substantially as more of
the population require treatment for allergies [6]. Ocular
allergy can itself produce irritating symptoms and severe
forms, such as atopic keratoconjunctivitis, could finally
lead to visual loss.
Allergic conjunctivitis is an inclusive term that encom-
passes seasonal allergic conjunctivitis (SAC), perennial
allergic conjunctivitis (PAC), vernal keratoconjunctivitis
(VKC), and atopic keratocongiuntivitis (AKC). However,
AKC and VKC have clinical and pathophysiological features
quite different from SAC and PAC, in spite of some com-
mon markers of allergy [7]. Also contact lenses or ocular
prosthesis associated giant papillary conjunctivitis (GPC)
are often included in the group of ocular allergy, however* Correspondence: mlarosa@unict.it
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reproduction in any medium, provided the orthey should not be considered as real allergic diseases, but
as chronic ocular micro-trauma related disorders, which
need to be managed by ophthalmologists in association
with contact lenses experts [8].
An understanding of the immunologic mechanisms,
clinical features, differential diagnosis, and treatment of
ocular allergy may be useful to all specialists who deal
with these patients. To this aim, we systematically
reviewed literature underlining all the forms classified as
ocular allergy.Allergic conjunctivitis
Seasonal and perennial allergic conjunctivitis
Seasonal allergic conjunctivitis (SAC) and perennial al-
lergic conjunctivitis (PAC) are the most common forms
of ocular allergies. Estimates vary, but these types of al-
lergy are said to affect at least 15–20% of the population
[9]. The presence of specific IgE antibodies to seasonal
or perennial allergen can be documented in almost all
cases of SAC and PAC [10].
Allergic conjunctivitis is caused by an allergen-induced
inflammatory response in which allergens interact with
IgE bound to sensitized mast cells resulting in the clin-
ical ocular allergic expression. The pathogenesis of allergic
conjunctivitis is predominantly an IgE-mediated hypersen-
sitivity reaction. Activation of mast cells induces enhancedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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trienes. This immediate or early response lasts clinically
20–30 min.
Mast cell degranulation also induces activation of vascular
endothelial cells, which in turn expresses chemokines and
adhesion molecules such as intercellular adhesion molecule
(ICAM), vascular cell adhesion molecule (VCAM). Other
chemokines secreted include regulated upon activation nor-
mal T cell expressed and secreted (RANTES) chemokines,
monocyte chemoattractant protein (MCP), interleukin (IL)-
8, eotaxin, macrophage inflammatory protein (MIP)-1 alpha.
These factors initiate the recruitment phase of inflam-
matory cells in the conjunctival mucosa, which leads to
the ocular late-phase reaction [11,12].
Signs and symptoms of the two conditions are the
same. The difference is the specific allergens to which
the patient is allergic. SAC is usually caused by airborne
pollens. Signs and symptoms usually occur in the spring
and summer, and generally abate during the winter
months. PAC can occur throughout the year with expos-
ure to perennial allergens. Diagnostic features of SAC
and PAC consist of itching, redness, and swelling of the
conjunctiva. Redness, or conjunctival injection, tends to
be mild to moderate (Figure 1). Conjunctival swelling, or
chemosis, tends to be moderate, and somewhat more
prominent than one would expect for a mild amount of
redness. Itching is a fairly consistent symptom of SAC
and PAC. Corneal involvement is rare [6].
Vernal keratoconjunctivitis
VKC is a disease of warm climates and warm weather
months [13,14]. It is more common in the tropics than
in northern climates. However, it is not unusual to see
occasional vernal conjunctivitis patients throughout the
United States and Canada. The prevalence of VKC in
Europe ranges from 1.2 to 10.6 cases per 10,000 popula-
tion, although the prevalence of associated corneal com-
plications is much lower (0.3-2.3 per 10,000 population)Figure 1 Seasonal and perennial allergic conjunctivitis: mild
conjunctival injection and moderate chemosis.[15]. Young people are typically affected [16]. In this form,
a nonspecific hyperreactivity occurs that explain the ocular
symptoms induced by nonspecific stimuli – such as wind,
dust and sunlight – as well as their variability, which is not
related to allergen levels in the environment. Indeed, skin
tests and/or serum IgE antibody tests to common allergens
are often negative [13].
VKC is a chronic allergic inflammation of the ocular
surface mediated mainly by Th2-lymphocyte; in a com-
plex pathogenesis have a role also the over-expression of
mast cells, eosinophils, neutrophils, Th2-derived cyto-
kines, chemokines, adhesion molecules, growth factors,
fibroblast and lymphocytes. IL-4 and IL-13 are involved
in the formation of giant papillae by inducing the pro-
duction of extra-cellular matrix and the proliferation of
conjunctival fibroblasts [11,17,18]. VKC has three clin-
ical forms: palpebral, limbal, and mixed, with an overall
preponderance in males.
Symptoms include ocular itching, redness, swelling and
discharge. Itching may be quite severe, and even incapaci-
tating. Patients have often photophobia, sometimes very se-
vere. The most characteristic sign is giant papillae on the
upper tarsal conjunctiva (Figure 2). These ‘cobblestone-like’
swellings may be several millimeters in diameter. Usually,
10–20 are found on the tarsal conjunctiva, and they can be
seen easily by ‘flipping’ the upper eyelid [7].
There may be a tenacious mucous discharge between the
giant papillae. As one might expect, the giant papillae are
filled with inflammatory cells and edema. Neutrophils,
plasma cells, mononuclear cells, and eosinophils are found
in abundance. There is also a great deal of mast cell activity
within the giant papillae. Mast cells may also be found in
the conjunctival epithelium, a location in which they are
not normally present. The tears of VKC patients contain
high levels of IgE and mast cell mediators [19,20]. Hista-
mine, leukotrienes, prostaglandins, and kinase may be
found in the tears of VKC patients. The cornea may be af-
fected in VKC. A punctate keratitis, known as keratitis
epithelialis vernalis of El Tobgy, may begin in the centralFigure 2 Vernal keratoconjunctivitis: giant papillae of the
upper tarsal conjunctiva.
Figure 4 Vernal conjunctivitis: trantas dots.
La Rosa et al. Italian Journal of Pediatrics 2013, 39:18 Page 3 of 8
http://www.ijponline.net/content/39/1/18corneal. The dots may coalesce to form syncytial opacity.
This often leads to a whitish or grayish plaque beneath the
epithelium (Figure 3). These vernal plaques may interfere
with vision and lead to central scarring of the cornea.
Plaques can be removed by superficial keratectomy, but
they rarely resolve without surgical intervention. Histologi-
cally, plaques consist of mucin and epithelial cells, which
are literally ground into the central cornea. Tranta’s dots
consist of clumps of necrotic eosinophils, neutrophils, and
epithelial cells. The dots represent almost pure collections
of eosinophils (Figure 4) [14]. These cells collect in crypts,
which are formed by invaginations at the junction of the
cornea and conjunctiva. Trantas dots tend to appear when
VKC is active, and disappear when symptoms abate [6].
Shield ulcers can occur in the superior sectors of the cor-
nea; these are noninfectious, oval-shaped circumscribed
epithelial ulcer with underlying stromal opacification. After
the ulcer heals, an anterior stromal opacity can persist.
The massive eosinophil infiltration and activation in
the conjunctiva is responsible for the corneal complica-
tions. Corneal epithelial punctate keratitis may evolve to
macroerosion, ulcers and plaques, which are all expres-
sions of epithelial toxicity extricated by epitheliotoxic
factors released by activated eosinophils [8].
Atopic keratoconjunctivitis
Atopic keratoconjunctivitis (AKC) is a bilateral chronic
inflammatory disease of the ocular surface and eyelid. Its
pathomechanism involves both a chronic degranulation
of the mast cell mediated by IgE, and immune mecha-
nisms mediated by Th1- and Th2-lymphocyte derived
cytokines. Also eosinophils and other inflammatory cells
play a role [10,11]. It is considered the ocular counter-
part of atopic dermatitis, or atopic eczema [21].
Eczematous lesions may be found on the eyelids, or
any place on the body. Skin lesions are red and elevated.Figure 3 Vernal conjunctivitis: corneal plaque.They often occur in the antecubital or popliteal regions.
Typically, eczematous lesions are itchy, and scratching
them makes them itchier. Ocular findings vary. The
eyelid skin may be chemotic with a fine sandpaper-like
texture (Figure 5). There may be mild, or severe, con-
junctival injection and chemosis [22]. Giant papillae
may, or may not, be present. Conjunctival scarring is
common. Trantas dots may also be present. AKC pa-
tients may also develop atopic cataracts. Typically, these
are anterior, shield-like cataracts, but nuclear, cortical
and even posterior subcapsular cataracts may develop.
Corticosteroid therapy in AKC patients may contribute
to cataract development [22]. However, atopic cataracts
were documented long before corticosteroids were avail-
able for medical use. It is not unusual for AKC patients
to have cataract surgery at a young age [23]. It may seem
that the appearance of VKC and AKC is similar. Both
may be associated with giant papillae and Trantas dots.
In fact, there probably is some overlap between these two
conditions. VKC, however, resolves by age 20 years,
whereas AKC can persist throughout life [6]. Many patientsFigure 5 Atopic keratoconjunctivitis.
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to common allergens.Figure 6 Giant papillary conjunctivitis.Contact allergy
Contact allergy, or allergic contact dermatitis, is not an IgE-
mediated allergy, and can be considered in a different cat-
egory than the before mentioned allergic conditions [24].
It is a type-IV delayed hypersensitivity response, that
occurs through interaction of antigens with Th1 and
Th2 cell subsets followed by release of cytokines [25].
It consists of two phases: sensitization (at the first
exposition to the allergen, with production of memory
T-lymphocytes), and elicitation of the inflammatory re-
sponse (at the re-exposure to the antigen, mediated by the
activation of memory allergen-specific T-lymphocytes).
In particular, in the sensitization phase, antigen present-
ing cells processed antigen-MHC class II complex inter-
acts with T-lymphocytes, resulting in the differentiation of
CD4+ T-lymphocyte into memory T-lymphocyte. In the
elicitation phase, the interaction between the antigen-
MHC-II complex and memory T-cells stimulates the pro-
liferation of T-cells. The memory T-lymphocytes during
proliferation release cytokines [26].
Th1 or Th2 derived cytokines perform different functions.
Th1 derived cytokines, such as IL-2, IL-3, IFN-γ, medi-
ates recruitment of macrophages. Th2 derived cytokine,
such as IL-4 and IL-5, participates in the activation and
chemotaxis of eosinophils [27,28]. Two novel Th cell
subsets, IL-17-producing Th cells (Th17 cells) and regu-
latory T cells (Treg cells) are also found to be contribu-
tors in the pathogenesis of conjunctivitis. However, the
role of these cells in the activation of mast cells has not
been identified clearly [29].
Allergens are generally simple chemicals, low molecular
weight substances that combine with skin protein to form
complete allergens. Examples include poison ivy, poison
oak, neomycin, nickel, latex, atropine and its derivatives.
Contact allergy involves the ocular surface, eyelids and
periocular skin,
Although contact allergic reactions usually occur on the
skin, including the skin of the eyelids, the conjunctiva may
also support contact allergic reactions. Initial sensitization
with a contact allergen may take several days. Upon re-
exposure to the allergen, an indurated, erythematous reac-
tion slowly develops. The reaction may peak 2–5 days after
re-exposure. The delay in development of the reaction is
due to the slow migration of lymphocytes to the antigen
depot. The term ‘delayed hypersensitivity’ is sometimes
given to these reactions, in contrast to ‘immediate hyper-
sensitivity’, a term which emphasizes the rapid development
of IgE antibody-mediated reactions. Contact allergic reac-
tions are generally associated with itching. Treatment con-
sists of withdrawing, and avoiding contact with allergen.Severe reactions can be treated with topical or systemic
corticosteroids [6].
Giant papillary conjunctivitis
Giant papillary conjunctivitis (GPC) is an inflammatory
disease characterized by papillary hypertrophy of the su-
perior tarsal conjunctiva; the appearance is similar to
vernal conjunctivitis [30], but there is no significant cor-
neal involvement (Figure 6).
GPC is not an allergic disease; the incidence of systemic
allergy in GPC patients is similar to that of the general
population, and the stimuli for the papillary conjunctival
changes are inert substances rather than allergens. For ex-
ample, GPC may be caused by limbal sutures, contact
lenses, ocular prostheses, and limbal dermoids [31]. When
these irritative stimuli are removed, the conjunctival papil-
lary changes resolve. The conjunctival tissues may contain
mast cells, basophils, or eosinophils, but not to the extent
of an allergic reaction. There is no increase in IgE or
histaimine in the tears of GPC patients. Since the advent of
disposable contact lenses, the frequency of GPC is low.It
appears that protein build-up on the surface of contact
lenses, and irregular edges were the main reason for the
close association between contact lenses and GPC [6], by
immune or mechanical mechanisms: in particular protein
deposits on the surface of the contact lens could become
antigenic and stimulate the production of IgE; mechanical
trauma and chronic irritation can determine the release of
some mediators (CXCL8 and TNF-α) from injured con-
junctival epithelial cells [9,32].
Diagnosis of allergic conjunctivitis
The diagnosis of ocular allergy is primarily clinical, but
there are laboratory tests that can be useful in sup-
porting the diagnosis [33]. Allergists can perform skin
testing for specific allergens by scratch tests or intradermal
injections of allergen. In-vitro tests for IgE antibodies to
specific allergens are widely used. Allergic tests would help
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Treatment options
Avoidance of the offending antigen is the primary behav-
ioral modification for all types of allergic conjunctivitis;
however, the eyes present a large surface area and thus it
is often impossible to avoid ocular exposure to airborne
allergens. Artificial tear substitutes provide a barrier func-
tion and help to improve the first-line defense at the level
of conjunctival mucosa. These agents help to dilute various
allergens and inflammatory mediators that may be present
on the ocular surface, and they help flush the ocular surface
of these agents. When avoidance of non-pharmacologic
strategies do not provide adequate symptom relief, pharma-
cologic treatments may be applied topically or given sys-
temically to diminish the allergic response.
The mainstay of the management of ocular allergy in-
volves the use of anti-allergic therapeutic agents such as
antihistamine, multiple action anti-allergic agents and mast
cell stabilizers. For example, the H1 topical antihistamine
levocabastine hydrochloride is effective in rapidly relieving
ocular inflammation when administered topically to the
eye [34,35]. Topical antihistamines competitively and re-
versibly block histamine receptors and relieve itching and
redness but only for a short time. These medications do
not affect other proinflammatory mediators, such as pros-
taglandins and leukotrienes, which remain uninhibited. A
limited duration of action necessitates frequent dosing of
up to 4 times per day, and topical antihistamines may be ir-
ritating to the eye, especially with prolonged use [36].
Combination treatments using decongestants with antihis-
tamines have been shown to be more effective, and are ad-
ministered to the eye as drops up to 4 times daily [37].
Decongestants act primarily as vasoconstrictors and are ef-
fective in reducing erythema, however, adverse effects
include burning and stinging on instillation, mydriasis, and
rebound hyperemia or conjunctivitis medicamentosa with
chronic use [37]. Therefore, these treatments are suitable
only for short-term symptom relief, and are not recom-
mended for use in narrow-angle glaucoma patients.
Mast cell stabilizers have a mechanism of action that is
unclear. They may increase calcium influx into the cell
preventing membrane changes and/or they may reduce
membrane fluidity prior to mast cell degranulation. End re-
sult is a decrease in degranulation of mast cells, which pre-
vents release of histamine and other chemotactic factors
that are present in the preformed and newly formed state.
Mast cell stabilizers do not relieve existing symptoms
and they can be used on a prophylactic basis to prevent
mast cell degranulation with subsequent exposure to the
allergen. Mast-cell stabilizing medications can also be ap-
plied topically to the eye, and may be suitable for more se-
vere forms of conjunctivitis. They require a loading periodduring which they must be applied before the antigen ex-
posure. Therefore, poor compliance should be taken into
account as a possible drawback.
In recents years have been introduced several multi-
modal anti-allergic agents, such as olopatadine, ketotifen,
azelastine and epinastine and bepostatine, that exert mul-
tiple pharmacological effects such as histamine receptor
antagonist action, stabilization of mast-cell degranulation
and suppression of activation and infiltration of eosino-
phils [38].
Ketotifen inhibits eosinophil activation, generation of
leukotrienes and cytokine release [39,40].
Azelastine is a selective second generation H1 receptor
antagonists, and also acts by inhibiting platelet activating
factor (PAF) and blocking expression of intercellular ad-
hesion molecule 1 (ICAM-1) [41]. Epinastine has effect
on both H1 and H2 receptors (the latter effect may be
beneficial in reducing the eyelid swelling), and also has
mast-cell stabilizing and anti-inflammatory effects [42].
These drugs are becoming the drug of choice for pro-
viding immediate symptomatic relief for patients with al-
lergic conjunctivitis.
When the abobe mentioned anti-allergic drugs do not
allow an adequate control of the allergic inflammatory
process, anti-inflammatory agents are used. Non-steroidal
anti-inflammatory drug (NSAIDs) can be used as additive
drugs, in order to,reduce the conjunctival hyperemia and
the pruritus, related in particular to prostaglandin D2 and
prostaglandin E2 [43].
Corticosteroids remain among the most potent
pharmacologic agents used in the more severe variants
of ocular allergy and are also effective in the treatment
of acute and chronic forms of AC [44-48]. Corticoste-
roids possess immunosuppressive and anti-proliferative
properties since they can hinder the transcription factor
that regulates the transcription of Th2-derived cytokine
genes and differentiation of activated T-lymphocytes into
Th2-lymphocytes. They have some limitations, including
ocular adverse effects, such as delayed wound healing,
secondary infection, elevated intraocular pressure, and
formation of cataract. These agents are therefore appro-
priate for short courses (up to 2 weeks); however, if
needed for longer durations, an eye examination should
be carried out, including baseline assessment of cataracts
and intraocular pressure measurement [3,49].
The efficacy of immunotherapy against ocular symptoms
precipitated by conjunctival antigen challenges was origin-
ally demonstrated in 1911 and this well-established method
may be considered for the long-term control of AC [50].
Although some more recent studies have focused on nasal
rather than ocular symptoms, others have confirmed the ef-
ficacy of immunotherapy against ocular symptoms [50-56].
Allergen-specific immunotherapy is an effective treat-
ment for patients with allergic rhinoconjunctivitis that
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jective of this treatment is to induce a clinical tolerance to
the specific allergen: it reduces the seasonal increases of
IgE specific for that allergen, and it increases the produc-
tion of specific IgG4 and IgA; such effects are mediated by
an increase of the production of IL-10 and TGF-β1 [57].
However, immune responses to allergen administra-
tion are not predictive of the effectiveness of the therapy
and the therapy itself can produce systemic reactions,
the incidence and severity of which vary dependent on
the type of allergen administered [58,59]. Traditionally,
immunotherapy is delivered via subcutaneous injection.
However, sublingual (oral) immunotherapy (SLIT) is gai-
ning momentum among allergists. SLIT requires further
evaluation for ocular allergy relief; it has been shown to
control ocular signs and symptoms, although ocular
symptoms may respond less well than nasal symptoms
[60-65]. Oral antihistamines are commonly used for the
therapy of nasal and ocular allergy symptoms. These
newer second-generation antihistamines are recommended
in preference to first-generation antihistamines because
they have a reduced propensity for adverse effects such as
somnolence [3]. Second-generation antihistamines can,
however, induce ocular drying, which may impair the pro-
tective barrier provided by the ocular tear film and thus ac-
tually worsen allergic symptoms [66,67]. It has therefore
been suggested that the concomitant use of an eye drop
may treat ocular allergic symptoms more effectively [67].
Intranasal corticosteroids are highly effective for treating
nasal symptoms of allergic rhinitis, but the evidence that
they may also be effective for the treatment of ocular
symptoms is inconsistent [68-70].
Pediatric allergic conjunctivitis
In the pediatric age, allergic conjunctivitis occurs fre-
quently, with a peak age in late childhood and young adult-
hood. Patients frequently have a history of other atopic
disease, such as eczema, asthma, or, most commonly, rhin-
itis. Symptoms include bilateral involvement, itching, tear-
ing, mucoid discharge, redness, mild eyelid edema, and
chemosis. AKC and VKC occur less commonly, but are po-
tentially more severe. Therefore, involvement of pediatric
ophthalmologists may be necessary to avoid preventable
vision loss in severe cases [71].
Conclusion
The term allergic conjunctivitis is an inclusive term that
encompasses different clinical entities based on the as-
sumption that the classical Type I hypersensitivity mech-
anism is responsible for all clinical forms of allergic eye
disease. However, IgE and non-IgE-mediated mecha-
nisms are involved in the development of ocular allergic
diseases. The multiple mediators, cytokines, chemokines,
receptors, proteases, growth factors, intracellular signals,regulatory and inhibitory pathways, and other unknown
factors and pathways are differently expressed in the dif-
ferent allergic disorders, inducing the different clinical
aspects, diagnostic features and response to treatment.
Therefore, a new classification system is desirable, pref-
erably derived from the varied pathophysiological mech-
anisms operating in the different forms of ocular allergy.
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